Maxime Dely – The French Transfusion landscape is Evolving
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”The French transfusion landscape is evolving
As hospital needs change and health sovereignty becomes a national priority, the 2024 Annual Report of the French Blood Establishment (EFS) highlights a major transformation in the country’s transfusion system.
Red blood cell use continues to decline
The number of red blood cell (RBC) units issued keeps decreasing:
- 2,081,938 units delivered in 2024
- -3.4 % compared to 2023
This trend reflects:
• More efficient use of transfusion indications
• Improved patient blood management
• Optimization of clinical practices
Plasma takes center stage
Conversely, plasma collection is growing rapidly:
- 867,127 liters of plasma for fractionation delivered in 2024 (+4.8%)
- +1.4 % plasma donors in one year
This growth supports the national strategy “Ambition Plasma”, with an ambitious goal:
1.4 million liters of plasma collected per year by 2028
To reach this target, EFS is:
• Progressively shifting from whole blood to plasma donations,
• Opening new donation centers and time slots,
• Expanding remote medical supervision (tele-assistance) to facilitate apheresis donations.
A strong and encouraging donor engagement
In 2024:
- 1,506,534 donors – including 17 % new donors
- 29 % under 30 years old – a promising new generation of donors
- A strong sense of commitment that secures the future of blood and plasma supply
The generational renewal is a key success factor for sustaining the transfusion system in the years to come.
A structural shift
2024 confirms a deep transformation:
- Fewer red blood cell transfusions
- More plasma collected, better utilized, and more strategic than ever
A crucial evolution to meet therapeutic needs, strengthen the national supply of plasma-derived medicines, and support France’s health sovereignty.
What’s next?
How can we accelerate this transition while maintaining donor loyalty and the right balance between all blood components?
I’d love to hear your insights, experiences, and perspectives.”
Stay updated with Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025